Journal Article Review Epublish 26 citations
PubMed: 38399960 DOI: 10.3390/v16020184
Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness.
Viruses 16(2)
Authors: Wenhao Liu, Zehong Huang, Jin Xiao, Yangtao Wu, Ningshao Xia, Quan Yuan
Affiliations
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361000, China.
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361102, China.
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361000, China. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361102, China.
Abstract
Over the last three years, the pandemic of COVID-19 has had a significant impact on people's lives and the global economy. The incessant emergence of variant strains has compounded the challenges associated with the management of COVID-19. As the predominant variant from late 2021 to the present, Omicron and its sublineages, through continuous evolution, have demonstrated iterative viral fitness. The comprehensive elucidation of the biological implications that catalyzed this evolution remains incomplete. In accordance with extant research evidence, we provide a comprehensive review of subvariants of Omicron, delineating alterations in immune evasion, cellular infectivity, and the cross-species transmission potential. This review seeks to clarify the underpinnings of biology within the evolution of SARS-CoV-2, thereby providing a foundation for strategic considerations in the post-pandemic era of COVID-19.
MeSH
Sars-Cov-2, Virology, Pandemics, Severe Acute Respiratory Syndrome-Related Coronavirus, Immune Evasion
Cited by
- Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants. MAbs, 2025
- What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era? Vaccines (Basel), 2024
- Genomic surveillance in Morocco tracks SARS-CoV-2 variant shift from Alpha to Omicron sublineage JN1. Npj Viruses, 2025
- SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer. Vaccine, 2025
- Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors. ACS Med Chem Lett, 2025
- 5,6-dihydroxyflavone exerts anti-betacoronavirus activity by blocking viral entry to host cells. Virus Res, 2025
- Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study. Hum Vaccin Immunother, 2024
- Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants. Mol Ther Methods Clin Dev, 2025
- Efficacy and Safety of Acupuncture for Post-COVID-19 Insomnia: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc, 2025
- Efficacy of Inactivated Bivalent SARS-CoV-2 Vaccines Targeting Ancestral Strain (ERAGEM), Delta, and Omicron Variants. Vaccines (Basel), 2025
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern. Vaccines (Basel), 2025
- Genomic epidemiology and evolutionary dynamics of the Omicron variant of SARS-CoV-2 during the fifth wave of COVID-19 in Pakistan. Front Cell Infect Microbiol, 2024
- Emergent group A evidences a survival strategy during interaction with immune effector cells. Infect Immun, 2024